AQST R&D to Revenue
Aquestive Therapeutics Inc · R&D to Revenue
AQST R&D to Revenue
Latest reported28.67%period ending
AQST Quarterly R&D/Revenue (32.51% → 28.67%)
Latest values, visible window
High-resolution chart · PNG
AQST r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 28.6707% | |
| 29.1015% | |
| 24.5563% | |
| 35.3713% | |
| 41.0377% | |
| 61.4794% | |
| 41.4342% | |
| 38.9086% | |
| 20.7075% | |
| 49.216% | |
| 21.8688% | |
| 24.5808% | |
| 26.2291% | |
| 31.8574% | |
| 40.0487% | |
| 28.1951% | |
| 39.1858% | |
| 38.8998% | |
| 39.7184% | |
| 35.5686% | |
| 27.7745% | |
| 32.8988% | |
| 61.8968% | |
| 87.8935% | |
| 17.7486% | |
| 49.6748% | |
| 18.6187% | |
| 40.7715% | |
| 73.2411% | |
| 34.0346% | |
| 33.7791% | |
| 34.175% | |
| 57.3952% | |
| 20.9346% | |
| 51.4227% | |
| 20.9386% | |
| 43.4123% | |
| 32.5079% |